Home  »  Finance   »  Analysts Predict Autolus Therapeutics plc (NASDAQ:...

Analysts Predict Autolus Therapeutics plc (NASDAQ: AUTL) Going Down?

Autolus Therapeutics plc (NASDAQ:AUTL) shares, rose in value on Thursday, 05/25/23, with the stock price down by -1.93% to the previous day’s close as strong demand from buyers drove the stock to $3.05.

Actively observing the price movement in the last trading, the stock closed the session at $3.11, falling within a range of $3.00 and $3.345. The value of beta (5-year monthly) was 1.58. Referring to stock’s 52-week performance, its high was $3.79, and the low was $1.60. On the whole, AUTL has fluctuated by 85.98% over the past month.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


With the market capitalization of Autolus Therapeutics plc currently standing at about $493.79 million, investors are eagerly awaiting this quarter’s results, scheduled for May 04, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.22, which is expected to increase to -$0.2 for fiscal year -$0.89 and then to about -$0.85 by fiscal year 2024. Data indicates that the EPS growth is expected to be 43.30% in 2024, while the next year’s EPS growth is forecast to be 4.50%.

Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $1.73 million, representing a decrease of -72.80% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that AUTL’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Buy.

11 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 3 analyst(s), 8 recommend it as a Buy and 0 called the AUTL stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AUTL currently trading nearly 32.96% and 50.04% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 71.50, while the 7-day volatility ratio is showing 11.05% which for the 30-day chart, stands at 10.89%. Furthermore, Autolus Therapeutics plc (AUTL)’s beta value is 1.50, and its average true range (ATR) is 0.25. The company’s stock has been forecasted to trade at an average price of $6.63 over the course of the next 52 weeks, with a low of $2.70 and a high of $12.00. Based on these price targets, the low is 11.48% off current price, whereas the price has to move -293.44% to reach the yearly target high. Additionally, analysts’ median price of $6.00 is likely to be welcomed by investors because it represents a decrease of -96.72% from the current levels.

A comparison of Autolus Therapeutics plc (AUTL) with its peers suggests the former has fared considerably weaker in the market. AUTL showed an intraday change of -1.93% in last session, and over the past year, it grew by 17.31%%. In comparison, Novan Inc. (NOVN) has moved lower at -5.00% on the day and was down -57.30% over the past 12 months. On the other hand, the price of Bristol-Myers Squibb Company (BMY) has fallen -1.39% on the day. The stock, however, is off -16.30% from where it was a year ago. Additionally, there is a loss of -1.77% for Gilead Sciences Inc. (GILD) in last trading while the stock has seen an overall depriciation of 20.67%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.88%. Meanwhile, the Dow Jones Industrial Slipped by -0.11%.

Data on historical trading for Autolus Therapeutics plc (NASDAQ:AUTL) indicates that the trading volumes over the past 10 days have averaged 1.51 million and over the past 3 months, they’ve averaged 604.14K. According to company’s latest data on outstanding shares, there are 173.07 million shares outstanding.

Nearly 8.45% of Autolus Therapeutics plc’s shares belong to company insiders and institutional investors own 30.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.74 million shares as on May 14, 2023, resulting in a short ratio of 1.26. According to the data, the short interest in Autolus Therapeutics plc (AUTL) stood at 0.43% of shares outstanding as of May 14, 2023; the number of short shares registered in Apr 13, 2023 reached 1.29 million. The stock has risen by 60.53% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AUTL stock heading into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *